Search results for " aggregation"

showing 10 items of 441 documents

Protein aggregation in congenital myopathies.

2011

Protein aggregation in congenital myopathies may be encountered among different myofibrillar myopathies such as granulofilamentous myopathy, cytoplasmic body myopathy, or spheroid body myopathy, which are designated as αB crystallinopathy, desminopathy, and myotilinopathy, respectively, according to the respective mutant proteins. Caps in cap disease and reducing bodies in reducing body myopathy were disclosed to contain numerous proteins. The multitude of diverse proteins aggregating within muscle fibers suggests impaired extralysosomal degradation of proteins, a disturbance of catabolism. The lack of different proteins accruing, but the mutant ones at an early age of affected patients in …

AdultCatabolismMutantInfantProtein aggregationBiologySarcomereActinsDesminBiochemistryChild PreschoolPediatrics Perinatology and Child HealthMyosinMutationmedicineHumansMutant ProteinsNeurology (clinical)medicine.symptomMyopathyMyofibrilChildActinMyopathies Structural CongenitalSeminars in pediatric neurology
researchProduct

Haemorheological parameters in young patients with acute myocardial infarction

2008

The role played by hemorheological alterations on acute myocardial infarction (AMI) in young patients remains a question of debate. We have carried out a case-control study of 84 AMI patients aged45 years and 135 sex and age matched controls, in which blood viscosity (BV), plasma viscosity (PV), erythrocyte aggregation (EA) performed with the Myrenne (EA0, EA1) and the Sefam aggregometer (Ta, AI10, gammaD), erythrocyte deformability (ED) along with fibrinogen (Fbg), C-reactive protein (CRP) and plasmatic lipids i.e. total cholesterol (T-Chol) and triglycerides (TG) were determined. AMI patients showed higher, Fbg, TG, EA0, EA1, IA10, gammaD and lower Ta than controls (p=0.029, p0.001, p=0.0…

AdultErythrocyte AggregationMaleRiskmedicine.medical_specialtyErythrocytesPhysiologyBlood viscosityMyocardial InfarctionErythrocyte aggregationErythrocyte DeformabilityPhysiology (medical)Internal medicineHumansMedicineErythrocyte deformabilityMyocardial infarctionbusiness.industryCase-control studyFibrinogenHematologyMiddle AgedBlood Viscositymedicine.diseaseC-Reactive ProteinCase-Control StudiesHemorheologyCardiologyPhysical therapyFemaleCardiology and Cardiovascular MedicinebusinessClinical Hemorheology and Microcirculation
researchProduct

Erythrocyte Membrane Phosphatidylserine Exposure in Obesity

2008

It has been suggested that increased erythrocyte membrane phosphatidylserine (PS) exposure could contribute to hypercoagulability and hemorheological disturbances in obesity. The aim of our study was to evaluate PS exposure in obese patients and in a control group and to correlate this with hemorheological properties, i.e., erythrocyte aggregability (EA) and deformability, and to evaluate the effect of weight loss on these parameters. An anthropometric and analytical evaluation was performed at baseline and after 3 months on a diet (very low-calorie diet for 4 weeks and low-calorie diet for 2 months) on 49 severe or morbid obese patients (37 women, 12 men) and 55 healthy volunteers (39 wome…

AdultErythrocyte AggregationMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Phosphatidylserinesmedicine.disease_causeErythrocyte aggregationFlow cytometrychemistry.chemical_compoundYoung AdultEndocrinologyWeight lossInternal medicineErythrocyte DeformabilityMalondialdehydeWeight LossMedicineErythrocyte deformabilityHumansObesityProtein PrecursorsNutrition and Dieteticsmedicine.diagnostic_testbusiness.industryErythrocyte MembranePhosphatidylserineMiddle AgedMalondialdehydePathophysiologyPeptide FragmentsOxidative StressEndocrinologychemistryCase-Control StudiesImmunologyFemaleProthrombinmedicine.symptombusinessOxidative stress
researchProduct

Erythrocyte aggregation in homozygous sickle cell disease

2014

Amparo Vayaa,∗, Susana Colladoa, Rafael Alisb,c and Maria-Angeles Dasid aHemorheology and Haemostasis Unit, Service of Clinical Pathology, La Fe University Hospital, Valencia, Spain bResearch Universitary Institute “Dr. Vina Giner”, Molecular and Mitochondrial Medicine, Catholic University of Valencia, “San Vicente Martir”, Valencia, Spain cFaculty of Medicine, Catholic University of Valencia “San Vicente Martir”, Valencia, Spain dPediatry Service, La Fe University Hospital, Valencia, Spain

AdultErythrocyte AggregationMalemedicine.medical_specialtyAdolescentbiologyPhysiologybusiness.industryAnemia Sickle CellHematologybiology.organism_classificationUniversity hospitalYoung AdultChild PreschoolPhysiology (medical)Family medicineHumansMedicineFemaleChildCardiology and Cardiovascular MedicinebusinessValenciaClinical Hemorheology and Microcirculation
researchProduct

Metabolic alterations in morbid obesity. Influence on the haemorheological profile.

2011

There are few studies on haemorheological disturbances in morbidly obese patients. The role played by the metabolic syndrome on the rheological profile of morbidly obese subjects has not yet been established, and it is not clear whether morbidly obese, but "metabolically healthy", show rheological alterations. We aimed to determine the whole rheological profile in 136 morbidly obese patients and 136 normo-weight volunteers, along with plasma lipids, inflammatory and insulin resistance parameters. Patients had statistically higher glucose, triglycerides, HbA1c, leptin, insulin, HOMA, CRP, leucocytes, fibrinogen, plasma viscosity (p0.001, respectively), erythrocyte aggregation at 3 s-1 (p = 0…

AdultErythrocyte AggregationMalemedicine.medical_specialtyPhysiologymedicine.medical_treatmentInflammationFibrinogenErythrocyte aggregationBody Mass IndexInsulin resistancePhysiology (medical)Internal medicinemedicineHumansBlood CoagulationMetabolic Syndromebusiness.industryInsulinLeptinBody WeightHematologymedicine.diseaseBlood ViscosityObesityObesity MorbidEndocrinologyHemorheologyFemaleMetabolic syndromemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical hemorheology and microcirculation
researchProduct

Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis.

2007

It is not well established whether haemorheological alterations constitute independent risk factors for deep vein thrombosis (DVT).We have determined in 149 DVT patients and in 185 control subjects the body mass index (BMI), the haemorheological profile: blood viscosity (BV), plasma viscosity (PV), fibrinogen (Fg), erythrocyte aggregation (EA), erythrocyte deformability (ED) and plasma lipids. In the crude analysis BMI, Fg, PV, EA, triglycerides (TG) and ApoB were statistically higher and HDL cholesterol (HDL-Chol) statistically lower in DVT patients than in controls. No differences in BV and ED were observed.After BMI adjustment, Fg, PV and EA remained statistically higher in DVT cases tha…

AdultErythrocyte AggregationMalemedicine.medical_specialtyTime FactorsDeep veinBlood viscosityHyperlipidemiasFibrinogenGastroenterologyRisk AssessmentBody Mass IndexDeep vein thrombosis; Lipids; Obesity; HaemorheologyRisk FactorsInternal medicineDeep vein thrombosisErythrocyte DeformabilityOdds RatioMedicineHumanscardiovascular diseasesObesityRisk factorTriglyceridesUNESCO::CIENCIAS MÉDICAS ::Patología::TrombosisVenous Thrombosisbusiness.industryFibrinogenHematologyOdds ratioMiddle Agedmedicine.diseaseBlood ViscosityThrombosisLipidsSurgeryHaemorheologymedicine.anatomical_structureCholesterolCase-Control StudiesHemorheologyHemorheologyFemalebusinessBody mass index:CIENCIAS MÉDICAS ::Patología::Trombosis [UNESCO]medicine.drugThrombosis and haemostasis
researchProduct

Plasma viscosity pattern and erythrocyte aggregation in two patients with congenital afibrinogenemia

2020

: In this case report, we examine the behavior of plasma viscosity, explored at high and low shear rates, and erythrocyte aggregation in two patients with congenital afibrinogenemia, a clinical disorder firstly described in 1920 and that has an estimated incidence of 1 : 1-200 0000. The two hemorheological parameters examined by us showed a marked decrease in both patients, in one of whom erythrocyte aggregation was even undetectable. Keeping in mind that spontaneous thrombosis (venous and arterial) has been often described in congenital afibrinogenemia, it can be hypothesized that the decrease in plasma viscosity and erythrocyte aggregation might cause a reduction of the endothelial synthe…

AdultErythrocyte Aggregationmedicine.medical_specialty030204 cardiovascular system & hematologyErythrocyte aggregationNitric oxidePlasmaYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineShear stressHumansPlasma viscositybusiness.industryPlasma viscosity afibrinogenemiaHematologyGeneral MedicineMiddle AgedAfibrinogenemiaBlood Viscositymedicine.diseaseCongenital afibrinogenemiaEndocrinologychemistryFemaleStress MechanicalbusinessSpontaneous thrombosis030215 immunology
researchProduct

Blood rheology during chemotherapy in patients with ovarian cancer.

1998

The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma viscosity, red blood cell aggregation under conditions of stasis and low shear) in addition to hemoglobin, hematocrit, leukocytes, platelets, and fibrinogen. At the same time the incidence of deep vein thrombosis was recorded before, during six cycles of first line cisplatinum/epirubicin/cyclophosphamide chemotherapy, and 2 months thereafter (two-months check-up). Only six pati…

AdultErythrocyte Aggregationmedicine.medical_specialtymedicine.drug_classDeep veinBlood viscosityVenographyLow molecular weight heparinAntineoplastic AgentsHematocritGastroenterologyHemoglobinsLeukocyte CountInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesVeinCyclophosphamideAgedEpirubicinOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryPlatelet CountFibrinogenHematologyHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseBlood ViscosityThrombosisSurgerymedicine.anatomical_structureHematocritHemorheologyFemaleCisplatinbusinessEpirubicinmedicine.drugThrombosis research
researchProduct

RDW in patients with systemic lupus erythematosus. Influence of anaemia and inflammatory markers

2013

Red blood cell distribution width (RDW) is a routine parameter that reflects size variations in erythrocytes. High RDW has been associated with cardiovascular events and inflammatory diseases. However, no studies evaluating the association of RDW with systemic lupus erythematosus (SLE) have been published. We aimed to explore the association of RDW with inflammatory markers in SLE. As SLE is often associated with anaemia, we considered this factor in order to know whether RDW is related with inflammation, anaemia or both in SLE. The study included 105 SLE patients (7 men, 98 women; aged 15-73 years) and 105 controls (9 men, 96 women; aged 18-71 years). Patients were divided according to ana…

AdultErythrocyte IndicesMalemedicine.medical_specialtyAdolescentPhysiologyInflammationFibrinogenErythrocyte aggregationGastroenterologyYoung Adultimmune system diseasesPhysiology (medical)Internal medicinemedicineHumansLupus Erythematosus SystemicIn patientYoung adultskin and connective tissue diseasesAgedRetrospective StudiesInflammationLupus erythematosusbusiness.industryAnemiaRetrospective cohort studyRed blood cell distribution widthHematologyMiddle Agedmedicine.diseaseImmunologyFemalemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1995

Abstract Thromboxane A 2 (TXA 2 ) biosynthesis is enhanced in the majority of patients with type IIa hypercholesterolemia. Because simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) was previously shown to reduce platelet aggregation and TXB 2 production ex vivo, we investigated TXA 2 biosynthesis and platelet function in 24 patients with type IIa hypercholesterolemia randomized to receive in a double-blind fashion simvastatin (20 mg/d) or placebo for 3 months. The urinary excretion of 11-dehydro-TXB 2 , largely a reflection of platelet TXA 2 production in vivo, was measured by a previously validated radioimmunoassay technique. Blood lipid levels and urinary 11-dehyd…

AdultMaleBlood lipoproteinSimvastatinmedicine.medical_specialtyPlatelet AggregationApolipoprotein BThromboxaneHypercholesterolemiaBlood lipidsThromboxane A2chemistry.chemical_compoundThromboxane A2Double-Blind MethodInternal medicinemedicineHumansPlateletLovastatinAgedbiologyChemistryCholesterolAnticholesteremic AgentsMiddle AgedLipid MetabolismCholesterolEndocrinologySimvastatinbiology.proteinFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinePlatelet Aggregation Inhibitorsmedicine.drug
researchProduct